nafamostat has been researched along with Cardiac Output, Low in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Cardiac Output, Low: A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, SJ | 1 |
| Kim, JB | 1 |
| Jung, SH | 1 |
| Choo, SJ | 1 |
| Chung, CH | 1 |
| Lee, JW | 1 |
1 other study available for nafamostat and Cardiac Output, Low
| Article | Year |
|---|---|
Outcomes of extracorporeal life support for low cardiac output syndrome after major cardiac surgery.
Topics: Adult; Aged; Anticoagulants; Area Under Curve; Benzamidines; Biomarkers; Cardiac Output, Low; Cardia | 2014 |